The center has a pharmaceutical chemistry department, a macromolecular biology department, a pharmacology department, a pharmacy department and a non-clinical department. It is mainly based on its own early discovery and druggability evaluation and screening system, combined with solid pharmaceutical development and expert resources, through investment, shareholding, Various models such as service shareholding and joint entrepreneurship are used to incubate various innovative drug projects and enhance the long-term imagination and value space of Baicheng Pharmaceutical's innovative drug sector in multiple dimensions. At present, the company is involved in the main aspects of innovative drug research and development such as new drug discovery, lead compound optimization, preclinical development, clinical registration application, and phase 1 clinical trials. It has multiple innovative drug projects under development, one of which has entered clinical phase 1 research (obtained the 2020 Project support from Zhejiang Provincial Key R&D Plan).
? 2021 杭州百誠醫藥科技股份有限公司. ALL RIGHTS RESERVED
浙ICP備13034926號-1
(浙)-非經營性-2022-0016 浙公網安備 33010802005916號
? 2021 杭州百誠醫藥科技股份有限公司. ALL RIGHTS RESERVED浙ICP備13034926號-1 (浙)-非經營性-2022-0016 浙公網安備 33010802005916號
You are welcome to contact us via the online form below.
We will answer your inquiries in various ways, and jointly provide customized professional consultation and solutions for your research and development needs.
